Ambulatory Inhalation Therapy in Obstructive Lung Diseases

Respiration

Volumn 64, Issue 2, 1997, Pages 121-130

  Roche, N ^a   Chinet, T ^a   Huchon, G ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Breath actuated inhalers; Chlorofluorocarbons; Dry powder inhalers; Inhalation therapy; Inspiratory flow rate; Lung deposition; Metered dose inhalers; Misuse; Obstructive lung diseases; Paradoxical bronchospasm; Spacers

Indexed keywords

CHLOROFLUOROCARBON;

AEROSOL; BRONCHOSPASM; CHRONIC OBSTRUCTIVE LUNG DISEASE; COORDINATION; DEVICE; DRUG EFFICACY; DRUG MISUSE; FLOW RATE; HUMAN; HUMIDITY; INHALATIONAL DRUG ADMINISTRATION; INHALER; OUTPATIENT CARE; PRIORITY JOURNAL; REVIEW; STRATOSPHERE; SUSPENSION;

AEROSOLS; CHLOROFLUOROCARBONS; HUMANS; LUNG DISEASES, OBSTRUCTIVE; NEBULIZERS AND VAPORIZERS; PATIENT COMPLIANCE;

EID: 0031053401     PISSN: 00257931     EISSN: 14230356     Source Type: Journal    
DOI: 10.1159/000196656     Document Type: Article

References (55)

1. Newhouse M: Advantages of pressurized canister metered dose inhalers, J Aerosol Med 1991: 4:139-150.
2. Grossman J: The evolution of inhaler technology, J Asthma 1994;31:55-64.
3. Gerritv TR: Pathophysiological and disease constraints on aerosol delivery: in Byron PR (ed): Respiratory drug delivery', Boca Raton, CRC Press, 1990, pp 1-38.
4. Newman SP, Pavia D, Clarke SW: How should a pressurized beta-adrenergic bronchodilator be inhaled? EurJ Respir Dis 1981;62:3-21.
5. Newman SP, Pavia D, Garland N, Clarke SW; Effects of various inhalation modes on the deposition of radioactive pressurized aerosols, EurJ Respir Dis 1982;63(suppl):57-65.
6. Thorsson L, Edsbäcker S, Conradson TB: Lung deposition of budcsonide from Turbuhaler is twice that from a pressurized metcrcd-dose inhaler (pMDl), Am J Respir Crit Care Med 1994:149:A219.
7. Dolovitch M, Ruffin RE, Roberts R, New-house MT: Optimal delivery of aerosols from metered dose inhalers, Chest 1981:80(suppl): 911-915.
8. Newman SP, Weisz AWB, Talace N, Clarke SW: Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique, Thorax 1991:46: 712-716.
9. Newman SP, Moren F, Trofast F., Talace N, Clarke SW: Deposition and clinical efficacy of terbutaline sulphate from Turbuhaler, a new multi-dose powder inhaler, Eur Respir J 1992: 2:247-252.
10. Newman SP, Millar AB, Lennard-Jones TR, Moren F, Clarke SW: Improvement of pressurised aerosol deposition with Ncbuhaler spacer device, Thorax 1984;39:935-941.
11. Newman SP, Moren F, Pavia D, Little F, Clarke SW: Deposition of pressurized suspension aerosols inhaled through extension devices, Am Rev Respir Dis 1981:124:317-320.
12. Newhouse MT, Dolovich MB: Control of asthma by aerosols, N Engl J Med 1986:315:870- 874.
13. Pierce R: Asthma aerosols and CFCs, Aust NZ J Med 1990:20:6-7.
14. Newman SP: Metered dose pressurized aerosols and the ozone layer, Eur Respir J 1990:3: 495-497.
15. Tansey IP: The challenges in the development of metered dose inhalation aerosols using ozone-friendly propellants, European Pharmaceutical Technology Conference, Düsseldorf, 1993.
16. Partridge MR: Metered-dose inhalers and CFCs: What respiratory physicians need to know, Respir Med 1994;88:645-647.
17. Houghton JT: Climate change: The IPCC assessment, Cambridge, Cambridge University Press, 1990.
18. Ayres JG, Bcnincasa C: Acute bronchocon-striction following the use of metered-dose inhalers in adult asthmatics, Thorax 1994;49: 402P-403P.
19. Yarbrough J, Mansfield LE, Ting S: Metered-dose inhaler induced bronchospasm in asthmatic patients, Ann Allergy 1985:55:25-27.
20. Engel T, Heinig JH, Mailing HJ, Scharling B, Nikander K, Madsen F: Clinical comparison of inhaled budcsonide delivered via pressurized metered dose inhaler or Turbuhaler, Allergy 1989:44:220-225.
21. Finnerty JP, Howarth JP: Paradoxical bron-choconstriction with nebulized albuterol but not with terbutaline, Am Rev Respir Dis 1993: 148:512-513.
22. Sterling GM, Batten JC: Effect of aerosol propellants and surfactants on airway resistance, Thorax 1969:24:228-231.
23. Shim C, Williams MH Jr.: Cough and wheezing from bedomethasone dipropionate aerosol are absent after triamcinolone acetonide, Ann Intern Med 1987;106:700-703.
24. McGiven DV, MacFarlan JT: Severe broncho-constriction after inhalation of budcsonide, Br Med J 1984;288:447.
25. Wilkinson JRW, Howarth PH, Roberts JA, Bradding P, Holgatc ST: Paradoxical broncho-constri:tion induced by vehicle in salmeterol metered-dose inhaler, Am Rev Respir Dis 1992:145:A739.
26. Thiessen B, Pedersen OF: Effect of freon inhalation on maximal expiratory flows and heart rhythms after treatment with salbutamol and ipratropium bromide, Eur J Respir Dis 1980: 61:156-161.
27. Jackson L, Stahl E, Holgatc ST: Terbutaline via pressurized metered dose inhaled (p-MDI) and Turbuhaler in highly reactive asthmatic patients, Eur Respir J 1994:7:1598-1601.
28. Lahdensuo A, Muittari A: Bronchodilator effects of a fcnotcrol metered-dose inhalor and fenoterol powder in asthmatics with poor inhaler technique, Eur J Respir Dis 1986:68: 332-335.
29. Lindgren S, Bake B, Larsson S: Clinical consequences of inadequate inhalation technique in asthma therapy, Eur J Respir Dis 1987:79:93- 98.
30. Chinet T, Huchon G: La mauvaise utilisation des acrosols-doseurs pressurisés dans le traitement des maladies bronchiques, Frequence et conséquences cliniques, Ann Méd Interne 1994:145:119-124.
31. Hanan a NA, Wittman R, Kestcn S, Chapman KR: Medical personnel's knowledge of and ability to use inhaling devices - Metered-dose inhalers, spacing chambers, and breath-actuated powder inhalers, Chest 1994:105:111- 116.
32. Kesten S, Elias M, Cartier A, Chapman KR: Patient handling of a multidose dry powder inhalation device for albuterol, Chest 1994: 105:1077-1081.
33. Liam CK, Lo YL, Yap BH, Low SH, Ariwala-gam M: Use of pressurised aerosol inhalers among patients attending the chest clinic and primary care department of university hospital, Kuala Lumpur, Med J Malaysia 1993:48: 273-279.
34. Goodman DE, Israel E, Rosenberg M, Johnston R, Weiss ST, Drazen JM: The influence of age, diagnosis and gender on proper use of metcrcd-dose inhalers, Am J Respir Crit Care Med 1994:150:1256-1261.
35. Thompson J, Irvine T, Grathwohl K, Roth B: Misuse of metered-dose inhalers in hospitalized patients, Chest 1994:105:715-717.
36. Liard R, Zureik N, Aubier M, Korobaess M, Henry C, Neukirch F: Misuse of pressurized metered dose inhalers by asthmatic patients treated in French private practice, Rev Epidem SamePubl 1995:43:242-249.
37. Lipworth BJ: New perspectives on inhaled drug delivery and systemic bioactivitv, Thorax 1995;50:105-110.
38. O'C'allaghan C, Cant M, Robertson C: Delivery of beclomethasone dipropionate from a spacer device: What dose is available for inhalation? Thorax 1994:49:961-964.
39. Moren F, Newman SP, Trofast E, Talaec N, Clarke SW: Pharmaceutical Conference, Stockholm, 1989.
40. Pedersen S: Xlllth International Congress of Allergology and Clinical Immunology, Montreux, 1988.
41. Engel T, Scharling B, Hcinig JH: Effects, side effects and plasma concentrations of terbuta-line in adult asthmatics after inhaling from a dry powder inhaler device at different inhalation flows and volumes, Br J Clin Pharmacol 1992:33:439-444.
42. Ross D: Effect of inhalation flow rate on the dosing characteristics of dry powder inhaler (DPI) and metered dose inhaler (MDI) products, Eur Respir J I994;7(suppl 18):A0551.
43. Engel T, Heinig JH, Madsen F, Nikander K: Peak inspiratory flow' and inspiratory vital capacity of patients with asthma measured with and without a new dry-powder inhaler device (Turbuhaler), Eur Respir J 1990:3:1037-1041.
44. Clark AR, Hollingworth AM: The relationship between powder inhaler resistance and peak inspiratory conditions in healthy volunteers -implications for in vitro testing, J Aerosol Med 1993;6:99-110.
45. Pedersen S, Hansen OR, Fuglsang G: Influence of inspiratory flow rate upon the effect of a turbuhaler, Arch Dis Child 1990:65:308-319.
46. Meakin BJ, Cainey J, Woodcock PM: Effect of exposure to humidity on terbutaline delivery from turbuhaler dry powder inhalation devices, Eur Respir J 1993;6:760-763.
47. Dockrell D, Rooney M, Kelly P, Clancy L: Choosing an alternative to the metered dose inhaler; the patient’s preference, Eur Respir J I993;6:594S.
48. Town GL, Epton MJ, Martin IR, Frost G: Comparative asthma control and certainty of dose delivery with two breath-actuated asthma inhalers, Eur J Clin Res 1994:5:161-169.
49. Girbino G, Lauriello G, Ando F, Cantini L: Effectiveness of a new spacer device for the administration of high-dosc inhaled beclo-mcthasonc dipropionate (BDP) in adult asthmatics, Eur Respir J 1995:8:202S.
50. Boulct LP, Mark S, Clay M: Comparative efficacy and tolerability of salmcterol from two dry powder inhalers in asthmatic adults, Am J Rcs-pir Crit Care Med 1995:141:A58.
51. Kemp JP, Hill MR, Vaughan I.M, Clauson V: Comparison in asthmatics of the bronchodila-tor response to inhaled albuterol delivered by MDI and novel dry powder inhaler, Am J Respir Crit Care Med 1995; 151:A59.
52. Donrell D, Harrison LI, Simmons J, Ekholm BP: 28-Day safety study of the HFA134-a Airomir™ CFC-free system in healthy volunteers, Am J Respir Crit Care Med 1995; 151: A57.
53. Bleecker ER, Klinger NM, Ekholm BP, Tin-kelman DG: Twelve week efficacy and safety comparison of salbutamol formulated with UFA 134a and standard CFC metered dose inhaler devices, Am J Respir Crit Care Med 1995:151:A58.
54. Pcrruchoud AP, Jones AL: A three month multi-national study comparing the efficacy and safety of fluticasone propionate propelled by chlorofluorocarbons 11 and 12 or an alternative propellant GR 106642X in adults, Am J Respir Crit Care Med 1995; 151:A61.
55. O'Connor BJ, Coulby U, Burnett L, Donnell D: Effect of HFA-134a beclomethasone (HFA-BDPi) on airway hyperresponsiveness to me-thacholine, Am J Respir Crit Care Med 1995: 151: A60.